What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Sell
22
HRTS Quote, Financials, Valuation and Earnings
Last price:
$29.70
Seasonality move
:
-1.57%
Day range:
$29.81 - $30.47
52-week range:
$28.56 - $36.03
Dividend yield:
0.48%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.2K
Avg. volume:
14.1K
1-year change:
-9.95%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
HART
NYLI Healthy Hearts ETF
|
-- | -- | -- | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$29.95 | -- | -- | -- | $0.47 | 0.48% | -- |
|
AGNG
Global X Aging Population ETF
|
$31.54 | -- | -- | -- | $0.15 | 0.79% | -- |
|
CANC
Tema Oncology ETF
|
$24.84 | -- | -- | -- | $0.73 | 2.01% | -- |
|
HART
NYLI Healthy Hearts ETF
|
$31.47 | -- | -- | -- | $0.15 | 1.3% | -- |
|
IXJ
iShares Global Healthcare ETF
|
$91.29 | -- | -- | -- | $0.62 | 1.41% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$53.55 | -- | -- | -- | $0.33 | 5.26% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 1.300 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.954 | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | 1.116 | -- | -- |
|
HART
NYLI Healthy Hearts ETF
|
-- | 0.953 | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | 1.049 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 1.080 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
HART
NYLI Healthy Hearts ETF
|
-- | -- | -- | -- | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
Tema GLP-1, Obesity & Cardiometabolic ETF vs. Competitors
-
Which has Higher Returns HRTS or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is HRTS or AGNG More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.797, suggesting its less volatile than the S&P 500 by 20.348%.
-
Which is a Better Dividend Stock HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.48%. Global X Aging Population ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $0.15 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or AGNG?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns HRTS or CANC?
Tema Oncology ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat Tema Oncology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- CANCTema Oncology ETF-- -- -- -
What do Analysts Say About HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Oncology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than Tema Oncology ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than Tema Oncology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 CANCTema Oncology ETF0 0 0 -
Is HRTS or CANC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Oncology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.48%. Tema Oncology ETF offers a yield of 2.01% to investors and pays a quarterly dividend of $0.73 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. Tema Oncology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or CANC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than Tema Oncology ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than Tema Oncology ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while Tema Oncology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for Tema Oncology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- CANCTema Oncology ETF-- -- -- --
-
Which has Higher Returns HRTS or HART?
NYLI Healthy Hearts ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat NYLI Healthy Hearts ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- HARTNYLI Healthy Hearts ETF-- -- -- -
What do Analysts Say About HRTS or HART?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand NYLI Healthy Hearts ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than NYLI Healthy Hearts ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than NYLI Healthy Hearts ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 HARTNYLI Healthy Hearts ETF0 0 0 -
Is HRTS or HART More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NYLI Healthy Hearts ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or HART?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.48%. NYLI Healthy Hearts ETF offers a yield of 1.3% to investors and pays a quarterly dividend of $0.15 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. NYLI Healthy Hearts ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or HART?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than NYLI Healthy Hearts ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than NYLI Healthy Hearts ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while NYLI Healthy Hearts ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for NYLI Healthy Hearts ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- HARTNYLI Healthy Hearts ETF-- -- -- --
-
Which has Higher Returns HRTS or IXJ?
iShares Global Healthcare ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat iShares Global Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- IXJiShares Global Healthcare ETF-- -- -- -
What do Analysts Say About HRTS or IXJ?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Global Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than iShares Global Healthcare ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than iShares Global Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 IXJiShares Global Healthcare ETF0 0 0 -
Is HRTS or IXJ More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Global Healthcare ETF has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.526%.
-
Which is a Better Dividend Stock HRTS or IXJ?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.48%. iShares Global Healthcare ETF offers a yield of 1.41% to investors and pays a quarterly dividend of $0.62 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. iShares Global Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or IXJ?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than iShares Global Healthcare ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than iShares Global Healthcare ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while iShares Global Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for iShares Global Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- IXJiShares Global Healthcare ETF-- -- -- --
-
Which has Higher Returns HRTS or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Tema GLP-1, Obesity & Cardiometabolic ETF's net margin of --. Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema GLP-1, Obesity & Cardiometabolic ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Tema GLP-1, Obesity & Cardiometabolic ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is HRTS or JDOC More Risky?
Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF has a quarterly dividend of $0.47 per share corresponding to a yield of 0.48%. JPMorgan Healthcare Leaders ETF offers a yield of 5.26% to investors and pays a quarterly dividend of $0.33 per share. Tema GLP-1, Obesity & Cardiometabolic ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRTS or JDOC?
Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Tema GLP-1, Obesity & Cardiometabolic ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Tema GLP-1, Obesity & Cardiometabolic ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema GLP-1, Obesity & Cardiometabolic ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 2.14% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 3.3% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 2.17% over the past day.
